Coen Steven P.

Coen Steven P. has demonstrated a consistent pattern of selling activity in shares of DNA (Ginkgo Bioworks Holdings, Inc.), as evidenced by SEC Form 4 filings spanning from July 2025 to March 2026. Over this period, Coen executed seven sell transactions totaling $136,529.78, with no recorded purchases. The largest single sale occurred on October 1, 2025, amounting to $84,135, followed by a $17,907.49 transaction on October 17, 2025. Smaller sales, such as $3,842.76 on August 22, 2025, and $4,768.38 on March 16, 2026, further underscore this trend. Notably, these sales were often preceded by multiple "M" code transactions, indicating the acquisition of shares through derivative securities like options or warrants, which were subsequently sold. The absence of buy transactions suggests a clear bias toward reducing holdings in DNA. This activity is concentrated exclusively in Ginkgo Bioworks, with no diversification into other companies. The timing of these transactions does not reveal a specific pattern, as sales occurred sporadically across several months. However, the consistent liquidation of shares, particularly the significant October 2025 sale, highlights a deliberate effort to divest from the company. Coen’s trading history, as reflected in these filings, provides a transparent view of a sustained sell-off strategy within a single equity position.